Merck (MRK) Tops Q2 EPS by 5c; Narrows and Raise FY15 EPS Outlook

Merck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.

Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.

“We’re investing resources to grow our strongest brands and to support the most promising assets in our pipeline, while at the same time lowering our cost base and delivering operating leverage.”

“We’ve made significant progress this quarter in two of our most important assets, the KEYTRUDA and hepatitis C programs, and will be fully prepared to take advantage of these potentially breakthrough opportunities.”

“We’re witnessing the introduction of breakthrough therapies for some of the most difficult-to-treat diseases. Merck’s late-stage pipeline and ongoing launches reflect scientific and therapeutic progress with the potential to provide significant value to patients and society.”

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• HP Inc. projects mid-single-digit PC market decline in 2027
• Streamflation drives 39% of Americans to cancel streaming in 6 months
• Faraday Future unveils nine robotics devices priced from $9,990